10.1016j.celrep.2017.02.011.ann

T1 Condition 674 677 Myc
T2 Gene 990 994 PD-1
T3 Gene 861 869 BETi JQ1
T4 Condition 172 198 Myc-driven B cell lymphoma
T5 Intervention 98 116 anti-cancer agents
T6 Protein 475 480 IFN-γ
T7 Gene 832 852 anti-PD-1 antibodies
T8 Biomarker 861 865 BETi
T9 Biomarker 603 607 BETi
T10 Protein 29 60 bromodomain-containing proteins
T11 Protein 1090 1095 CD274
T12 Biomarker 369 384 Myc-independent
T13 Protein 457 473 interferon-gamma
T14 Biomarker 162 166 BETi
T15 Organism 524 556 human and mouse tumor cell lines
T16 Gene 808 813 PD-L1
T17 Gene 837 841 PD-1
T18 Biomarker 404 408 BETi
T19 Biomarker 272 276 BETi
T20 Protein 744 754 Cd274 mRNA
T21 Protein 0 14 BET inhibitors
T22 Condition 172 175 Myc
T23 Protein 272 284 BETi-induced
T24 Biomarker 386 390 BETi
T25 Protein 325 356 immune checkpoint ligand Cd274 
T26 Gene 995 1018 PD-L1 immune-checkpoint
T27 Gene 803 807 PD-1
T28 Condition 369 372 Myc
T29 Gene 995 1000 PD-L1
T30 Protein 640 651 Cd274 locus
T31 Protein 490 495 CD274
T32 Biomarker 977 981 BETi
T33 Condition 915 918 Myc
T34 Biomarker 16 20 BETi
T35 Organism 902 935 mice bearing Myc-driven lymphomas
T36 Organism 569 584 patient samples
R1 Relation Arg1:T14 Arg2:T22